日本已有若干公司根据遗传工程学生产重组促红细胞生成素,现正在进行第二期到第三期试验阶段。第二期试验是以人工透析的慢性肾衰患者为对象,改善贫血效果明显。在投给重组促红细胞生成素后不久红细胞数、红细胞压积即开始上升,在2～3个月内,于投给促红细胞生成素前为20％以下的红细胞压积超过了30％。患者的自觉症状也随之明显改善。尤为引人关注的是以往因贫血进展需定期输血的透析患者几乎无需输血。如从输血的副作 There are several companies in Japan that produce recombinant erythropoietin according to genetic engineering and are currently conducting Phase II to Phase III trials. The second phase of the trial is based on artificial dialysis patients with chronic renal failure, improvement of anemia obvious effect. Erythropoietin shortly after administration of recombinant erythropoietin, hematocrit began to rise within 2 to 3 months, before administration of erythropoietin 20% or less hematocrit over 30%. Patients with symptoms also will be significantly improved. Of particular concern is the almost no need for blood transfusions in dialysis patients who have had regular blood transfusions due to anemia. Such as blood transfusions